#United States #AI Innovations #New Orleans #Verana Health #Ophthalmology Research

Verana Health Unveils Significant Innovations in Ophthalmology

Verana Health®, a pioneering digital health company, has announced groundbreaking advancements in its data and software solutions aimed at enhancing ophthalmologic research and treatment optimization. These innovations, unveiled in conjunction with the upcoming American Academy of Ophthalmology (AAO) annual meeting in New Orleans, are set to revolutionize patient care and clinical research through the utilization of real-world data (RWD).

Transformative Solutions for Patient Care

Sujay Jadhav, CEO of Verana Health, expressed the company's commitment to leveraging technology and data-driven approaches to advance ophthalmic research. The recent developments equip both clinicians and life science entities with precise tools necessary for accelerating discoveries and improving patient outcomes.

Among the notable enhancements is the collaboration with Bitfount, which simplifies the prescreening process for ophthalmic clinical trials. This integration merges ophthalmic imaging with Electronic Health Record (EHR) data, significantly increasing the efficiency of identifying eligible participants for studies. By assessing integrated patient imaging against established protocol criteria, they ensure a pre-validated patient pipeline for clinical trials, ultimately expediting the enrollment process.

Expanded Data Availability

Furthermore, Verana Health has introduced new datasets and variables in its Ophthalmology Qdata collection. These fit-for-purpose modules drawn from the IRIS Registry encompass crucial data pertaining to the patient experience. Newly launched datasets focus on conditions like Retinal Vein Occlusion and Stargardt Disease, alongside additional variables related to glaucoma and other eye health issues that are available upon request.

Another innovative solution is Agent Claire, which facilitates a conversational interface to access disease-specific datasets (e.g., neovascular Age-related Macular Degeneration, diabetic retinopathy) without requiring specialized programming skills. This empowers various teams to ask insightful questions quickly, enabling them to harness the power of real-world evidence to inform their strategies in clinical settings.

Enhancing Ophthalmic Imaging Initiatives

Verana Health is also advancing its ophthalmic imaging project through the Imaging Consortium. This initiative focuses on developing the required infrastructure to securely integrate imaging data with clinical records from the IRIS Registry. The company is working in collaboration with leading academic institutions and community ophthalmology practices to expand its imaging contributions, ultimately creating a more comprehensive multimodal data resource.

Engagement at AAO 2026

During the AAO 2026 event, Verana Health plans to showcase a range of its new products and services. Attendees will have access to overviews of MIPS Advisory Services tailored for ophthalmologists, as well as findings from a collaborative research study with Amgen analyzing treatment patterns for Thyroid Eye Disease. This includes real-world data before and after the introduction of teprotumumab, a significant new therapy.

Verana Health will also present on AI's role in transforming routine clinical operations, emphasizing how AI enables healthcare providers to better manage responsibilities while ensuring comprehensive compliance with MIPS requirements. By participating in the IRIS Registry, clinicians are empowered to devote more time to patient care while effortlessly adhering to evolving regulatory standards.

In conclusion, Verana Health's commitment to innovation through enhanced data-driven insights is shaping the future of ophthalmology, fostering advancements in patient care and clinical research efficiency. For more insights, professionals can visit their booth at AAO 2026 or explore further at veranahealth.com.